AC Immune’s ACI-19764 reaches the brain in Phase 1 as NLRP3 programme moves beyond healthy volunteers
Preliminary Phase 1 data showed brain exposure, a half-life above 30 hours and dose-dependent IL-1β inhibition for AC Immune’s oral NLRP3 inhibitor ACI-19764.